Table 2.
Baseline characteristics at index date for patients who initiated abatacept or tocilizumab during the 2010–2019 time period*
| Abatacept | Tocilizumab | |||||
|---|---|---|---|---|---|---|
| ACPA− (n = 324) |
ACPA+ (n = 475) |
P | ACPA− (n = 146) |
ACPA+ (n = 258) |
P | |
| Age, years | 59.4 (13.6) | 59.1 (12.6) | 0.745 | 57.0 (13.8) | 55.9 (12.7) | 0.414 |
| Female, n (%) | 272 (84.2)a | 378 (79.6) | 0.098 | 106 (72.6) | 204 (79.1) | 0.139 |
| Duration of RA, years | 8.8 (9.0) | 10.6 (9.8) | 0.008 | 9.2 (8.8) | 11.1 (9.9) | 0.054 |
| RF+, n (%)b | 102 (34.7) | 346 (83.6) | < 0.001 | 53 (40.2) | 180 (78.6) | < 0.001 |
| Erosive disease, n (%)c | 109 (36.1) | 168 (39.8) | 0.310 | 53 (38.7) | 85 (35.7) | 0.566 |
| ACR functional class III/IV, n (%) | 46 (14.2) | 98 (20.6) | 0.020 | 21 (14.4) | 59 (22.9) | 0.040 |
| History of comorbidities, n (%) | ||||||
| Diabetes | 37 (11.4) | 50 (10.5) | 0.691 | 11 (7.5) | 25 (9.7) | 0.465 |
| Malignancies | 38 (11.7) | 38 (8.0) | 0.078 | 9 (6.2) | 11 (4.3) | 0.397 |
| CVD | 46 (14.2) | 65 (13.7) | 0.837 | 25 (17.1) | 26 (10.1) | 0.041 |
| Prior b/tsDMARDs, n (%) | ||||||
| 0 | 57 (17.6) | 80 (16.8) | 0.782 | 12 (8.2) | 24 (9.3) | 0.714 |
| 1 | 93 (28.7) | 152 (32.0) | 0.321 | 56 (38.4) | 96 (37.2) | 0.819 |
| ≥ 2 | 174 (53.7) | 243 (51.2) | 0.479 | 78 (53.4) | 138 (53.5) | 0.990 |
| CDAI score (0–76) | 24.0 (12.5) | 22.3 (13.0) | 0.065 | 25.3 (14.2) | 22.2 (14.3) | 0.037 |
| Patient global assessment, VAS 0–100 mm | 51.9 (24.5) | 48.7 (25.5) | 0.076 | 53.9 (23.4) | 50.9 (26.9) | 0.251 |
| mHAQ score (0–3) | 0.6 (0.5) | 0.6 (0.5) | 0.821 | 0.7 (0.5) | 0.7 (0.6) | 0.996 |
| Patient pain, VAS 0–100 mm | 54.6 (26.1) | 51.8 (27.2) | 0.148 | 55.8 (26.5) | 52.7 (28.3) | 0.292 |
| Patient fatigue, VAS 0–100 mm | 55.3 (27.6) | 52.8 (29.0) | 0.233 | 54.9 (29.0) | 55.3 (29.0) | 0.893 |
| Current therapy, n (%) | ||||||
| Monotherapy | 91 (28.1) | 142 (29.9) | 0.581 | 47 (32.2) | 68 (26.4) | 0.212 |
| Combination therapy with MTX only | 117 (36.1) | 191 (40.2) | 0.242 | 60 (41.1) | 119 (46.1) | 0.328 |
| Current prednisone use, n (%) | 102 (31.5) | 175 (36.8) | 0.118 | 42 (28.8) | 89 (34.5) | 0.237 |
Data are mean (SD) unless stated otherwise. *Patients who initiated abatacept or tocilizumab from February 1, 2010 to February 28, 2019
an = 323
bRF and ACPA testing are not required for all patients in the RA Registry; therefore, these counts are only available for a reduced number of patients; abatacept n = 294 and 414, tocilizumab n = 132 and 229, for ACPA– and ACPA+, respectively
cAbatacept n = 302 and 422, tocilizumab n = 137 and 238, for ACPA– and ACPA+ , respectively
ACR American College of Rheumatology, ACPA+ anti-citrullinated protein antibody positive (anti-CCP2 ≥ 20 U/ml), ACPA− anti-citrullinated protein antibody negative (anti-CCP2 < 20 U/ml), anti-CCP2 anti-cyclic citrullinated peptide-2, b/tsDMARD biologic or targeted-synthetic disease-modifying antirheumatic drug, CDAI Clinical Disease Activity Index, CVD cardiovascular disease, mHAQ modified Health Assessment Questionnaire, MTX methotrexate, RA rheumatoid arthritis, RF+ rheumatoid factor positive, SD standard deviation, VAS visual analog scale
Table adapted from Harrold LR, et al. ACR/ARP Annual Meeting; November 8–13, 2019; abstract number: 1386. Reprinted from ACR Convergence held November 8–13, 2019. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by Springer